Bioactive peptides - are there more antihypertensive mechanisms beyond ace inhibition?

Current Pharmaceutical Design

Volumn 18, Issue 30, 2012, Pages 4706-4713

  Marques, Cláudia ^a   Amorim, Maria Manuela ^b   Pereira, Joana Odila ^b   Pintado, Manuela Estevez ^b   Moura, Daniel ^a,c   Calhau, Conceição ^a   Pinheiro, Hélder ^a,d  

^a University of Porto   (Portugal)

^b CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

ACE; Bioactive peptides; Biopeptides; Hypertension; Mechanisms of action; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; CAY 10441; CGEN 856S; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; EGG PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FERRITIN; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOLEUCINE; LORGLUMIDE; MILK PROTEIN; NITRIC OXIDE; NOVOKININ; NUTRACEUTICAL; PEPTIDE; PEPTIDE RIY; PROLINE; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN SYNTHASE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VALINE; VALYLTYROSINE;

BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAPESEED; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIETARY PROTEINS; HUMANS; HYPERTENSION; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RENIN-ANGIOTENSIN SYSTEM;

EID: 84866414933     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802651670     Document Type: Review

References (65)

1. Brower V. Nutraceuticals: Poised for a healthy slice of the healthcare market? Nat Biotechnol 1998; 16: 728-731.
2. Kalra EK. Nutraceutical--definition and introduction. AAPS PharmSci 2003; 5: E25.
3. Health Canada [homepage on the Internet]. Nutraceuticals/Functional Foods and Health Claims On Foods: Policy Paper [cited 2012 March 12 ]. Available from: http://www.hc-sc.gc.ca/fnan/label-etiquet/claims-reclam/nutra-funct_foods-nutrafonct_aliment-eng.php.
4. U.S. Food and Drug Administration [homepage on the internet]. The dietary supplement health and education act of 1994 [cited 2012 March 12]. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/ederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003.htm.
5. Dietitians of Canada [homepage on the internet]. What are functional foods and nutraceuticals [cited 2012 March 12]. Available from: http://www.dietitians.ca/Nutrition-Resources-A-Z/Factsheets/Miscellaneous/Functional-foods-and-nutraceuticals.aspx.
6. Biesalski HK, Dragsted LO, Elmadfa I, et al. Bioactive compounds: Definition and assessment of activity. Nutrition 2009; 25: 1202-1205.
7. Moller NP, Scholz-Ahrens KE, Roos N, Schrezenmeir J. Bioactive peptides and proteins from foods: indication for health effects. Eur J Nutr 2008; 47: 171-182.
8. Arai S. Studies on functional foods in Japan--state of the art. Biosci Biotechnol Biochem 1996; 60: 9-15.
9. Roberfroid MB. A European consensus of scientific concepts of functional foods. Nutrition 2000; 16: 689-691.
10. De Leo F, Panarese S, Gallerani R, Ceci LR. Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food. Curr Pharm Des 2009; 15: 3622-3643.
11. Miguel M, Recio I, Gomez-Ruiz JA, Ramos M, Lopez-Fandino R. Angiotensin I-converting enzyme inhibitory activity of peptides derived from egg white proteins by enzymatic hydrolysis. J Food Prot 2004; 67: 1914-1920.
12. Senevirathne M, Kim SK. Development of bioactive peptides from fish proteins and their health promoting ability. Adv Food Nutr Res 2012; 65: 235-248.
13. Hernandez-Ledesma B, del Mar Contreras M, Recio I. Antihypertensive peptides: production, bioavailability and incorporation into foods. Adv Colloid Interface Sci 2011; 165: 23-35.
14. Marczak ED, Usui H, Fujita H, et al. New antihypertensive peptides isolated from rapeseed. Peptides 2003; 24: 791-798.
15. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-236.
16. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
17. Guimaraes S, Pinheiro H. Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally. Cardiovasc Res 2005; 67: 208-215.
18. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-672.
19. Avila MD, Morgan JP, Yan X. Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure. J Biomed Biotechnol 2011; 2011: 141039.
20. Ruiz-Ortega M, Esteban V, Suzuki Y, et al. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl 2003: S21-S26.
21. Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res 2001; 88: 654-658.
22. Ohkubo N, Matsubara H, Nozawa Y, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-3962.
23. Chappell MC. Emerging evidence for a functional angiotensinconverting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 2007; 50: 596-599.
24. Santos RA, Ferreira AJ, Simoes e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93: 519-527.
25. Weisinger RS, Begg DP, Jois M. Antagonists of the reninangiotensin system and the prevention of obesity. Curr Opin Investig Drugs 2009; 10: 1069-1077.
26. Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev 2006; 86: 747-803.
27. Campbell DJ. The renin-angiotensin and the kallikrein-kinin systems. Int J Biochem Cell Biol 2003; 35: 784-791.
28. Kuhr F, Lowry J, Zhang Y, Brovkovych V, Skidgel RA. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010; 44: 145-154.
29. Nakamura Y, Yamamoto N, Sakai K, et al. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 1995; 78: 777-783.
30. Sipola M, Finckenberg P, Santisteban J, et al. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol 2001; 52: 745-754.
31. Sipola M, Finckenberg P, Korpela R, Vapaatalo H, Nurminen ML. Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res 2002; 69: 103-111.
32. Wuerzner G, Peyrard S, Blanchard A, Lalanne F, Azizi M. The lactotripeptides isoleucine-proline-proline and valine-prolineprolineo not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. J Hypertens 2009; 27: 1404-1409.
33. Yamaguchi N, Kawaguchi K, Yamamoto N. Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur J Pharmacol 2009; 620: 71-77.
34. Ehlers PI, Kivimaki AS, Turpeinen AM, Korpela R, Vapaatalo H. High blood pressure-lowering and vasoprotective effects of milk products in experimental hypertension. Br J Nutr 2011; 106: 1353-1363.
35. Ehlers PI, Nurmi L, Turpeinen AM, Korpela R, Vapaatalo H. Casein- derived tripeptide Ile-Pro-Pro improves angiotensin-(1-7)- and bradykinin-induced rat mesenteric artery relaxation. Life Sci 2011; 88: 206-211.
36. Contreras MD, Carron R, Montero MJ, Ramos M, Recio I. Novel casein-derived peptides with antihypertensive activity. Int Dairy J 2009; 19: 566-573.
37. Sanchez D, Kassan M, Contreras Mdel M, et al. Long-term intake of a milk casein hydrolysate attenuates the development of hypertension and involves cardiovascular benefits. Pharmacol Res 2011; 63: 398-404.
38. Quinones M, Muguerza B, Miguel M, Aleixandre A. Evidence that nitric oxide mediates the blood pressure lowering effect of a polyphenol-rich cocoa powder in spontaneously hypertensive rats. Pharmacol Res 2011; 64: 478-481.
39. Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a metaanalysis of current available clinical trials. J Hum Hypertens 2011; 25: 425-436.
40. Boelsma E, Kloek J. Lactotripeptides and antihypertensive effects: a critical review. Br J Nutr 2009; 101: 776-786.
41. Miguel M, Aleixandre MA, Ramos M, Lopez-Fandino R. Effect of simulated gastrointestinal digestion on the antihypertensive properties of ACE-inhibitory peptides derived from ovalbumin. J Agric Food Chem 2006; 54: 726-731.
42. Miguel M, Manso M, Aleixandre A, et al. Vascular effects, angiotensin I-converting enzyme (ACE)-inhibitory activity, and antihypertensive properties of peptides derived from egg white. J Agric Food Chem 2007; 55: 10615-10621.
43. Miguel M, Alvarez Y, Lopez-Fandino R, Alonso MJ, Salaices M. Vasodilator effects of peptides derived from egg white proteins. Regul Pept 2007; 140: 131-135.
44. Matsui T, Imamura M, Oka H, et al. Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. J Pept Sci 2004; 10: 535-545.
45. Matsui T, Hayashi A, Tamaya K, et al. Depressor effect induced by dipeptide, Val-Tyr, in hypertensive transgenic mice is due, in part, to the suppression of human circulating renin-angiotensin system. Clin Exp Pharmacol Physiol 2003; 30: 262-265.
46. Tanaka M, Matsui T, Ushida Y, Matsumoto K. Vasodilating effect of di-peptides in thoracic aortas from spontaneously hypertensive rats. Biosci Biotechnol Biochem 2006; 70: 2292-2295.
47. Vercruysse L, Morel N, Van Camp J, Szust J, Smagghe G. Antihypertensive mechanism of the dipeptide Val-Tyr in rat aorta. Peptides 2008; 29: 261-267.
48. Toshiro M, Ueno T, Tanaka M, et al. Antiproliferative action of an angiotensin I-converting enzyme inhibitory peptide, Val-Tyr, via an L-type Ca2+ channel inhibition in cultured vascular smooth muscle cells. Hypertens Res 2005; 28: 545-552.
49. Wang Z, Watanabe S, Kobayashi Y, Tanaka M, Matsui T. Trp-His, a vasorelaxant di-peptide, can inhibit extracellular Ca2+ entry to rat vascular smooth muscle cells through blockade of dihydropyridinelike L-type Ca2+ channels. Peptides 2010; 31: 2060-2066.
50. Tanaka M, Tokuyasu M, Matsui T, Matsumoto K. Endotheliumindependent vasodilation effect of di- and tri-peptides in thoracic aorta of Sprague-Dawley rats. Life Sci 2008; 82: 869-875.
51. Erdmann K, Grosser N, Schipporeit K, Schroder H. The ACE inhibitory dipeptide Met-Tyr diminishes free radical formation in human endothelial cells via induction of heme oxygenase-1 and ferritin. J Nutr 2006; 136: 2148-2152.
52. Kawasaki T, Seki E, Osajima K, et al. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J Hum Hypertens 2000; 14: 519-523.
53. Savergnini SQ, Beiman M, Lautner RQ, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 2010; 56: 112-120.
54. Yamada Y, Iwasaki M, Usui H, et al. Rapakinin, an antihypertensive peptide derived from rapeseed protein, dilates mesenteric artery of spontaneously hypertensive rats via the prostaglandin IP receptor followed by CCK(1) receptor. Peptides 2010; 31: 909-914.
55. Yamada Y, Matoba N, Usui H, Onishi K, Yoshikawa M. Design of a highly potent anti-hypertensive peptide based on ovokinin(2-7). Biosci Biotechnol Biochem 2002; 66: 1213-1217.
56. Yamada Y, Yamauchi D, Usui H, et al. Hypotensive activity of novokinin, a potent analogue of ovokinin(2-7), is mediated by angiotensin AT(2) receptor and prostaglandin IP receptor. Peptides 2008; 29: 412-418.
57. Yamada Y, Yamauchi D, Yokoo M, et al. A potent hypotensive peptide, novokinin, induces relaxation by AT2- and IP-receptordependent mechanism in the mesenteric artery from SHRs. Biosci Biotechnol Biochem 2008; 72: 257-259.
58. Zhao H, Usui H, Ohinata K, Yoshikawa M. Met-Arg-Trp derived from Rubisco lowers blood pressure via prostaglandin D(2)-dependent vasorelaxation in spontaneously hypertensive rats. Peptides 2008; 29: 345-349.
59. Wu J, Aluko RE, Nakai S. Structural requirements of Angiotensin I-converting enzyme inhibitory peptides: quantitative structureactivity relationship study of di- and tripeptides. J Agric Food Chem 2006; 54: 732-738.
60. Quiros A, del Mar Contreras M, Ramos M, Amigo L, Recio I. Stability to gastrointestinal enzymes and structure-activity relationship of beta-casein-peptides with antihypertensive properties. Peptides 2009; 30: 1848-1853.
61. Garcia-Redondo AB, Roque FR, Miguel M, Lopez-Fandino R, Salaices M. Vascular effects of egg white-derived peptides in resistance arteries from rats. Structure-activity relationships. J Sci Food Agric 2010; 90: 1988-1993.
62. Matsufuji H, Matsui T, Seki E, et al. Angiotensin I-converting enzyme inhibitory peptides in an alkaline protease hydrolyzate derived from sardine muscle. Biosci Biotechnol Biochem 1994; 58: 2244-2245.
63. Matsui T, Tanaka M. Antihypertensive Peptides and Their Underlying Mechanisms. In: Mine Y, Li-Chan E, Jiang B. Eds. Bioactive Proteins and Peptides as Functional Foods and Nutraceuticals. Ames: Blackwell Publishing Ltd. and Institute of Food Technologists 2010; pp. 43-54.
64. Miguel M, Manso MA, Lopez-Fandino R, Alonso MJ, Salaices M. Vascular effects and antihypertensive properties of kappa-casein macropeptide. Int Dairy J 2007; 17: 1473-1477.
65. Hirota T, Nonaka A, Matsushita A, et al. Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart Vessels 2011; 26: 549-556.